

**IN VITRO ACTIVITY OF RIFAMPICIN AGAINST CLINICAL ISOLATES OF
MYCOBACTERIUM TUBERCULOSIS**

Thapa B^{1*}, Mahat K²

¹SAARC Tuberculosis and HIV/AIDS Centre, Thimi, Nepal

²WHO Country Office, Nepal

Correspondence:

Dr. Badri Thapa

MBBS, PhD (Medical Microbiology)

Microbiologist

SAARC Tuberculosis and HIV/AIDS Centre

Thimi, Bhaktapur, Nepal

977-1-6632601

badri_bishal@yahoo.com

Word count (excluding titles, references, tables and figures): 2500

No. of figures: 1

No. of tables: 2

(Second Page: Abstract and key words)

ABSTRACT


Introduction:.....
.....
.....

Methodology:.....
.....
.....
.....

Results:.....
.....
.....
.....

Conclusions:.....
.....
.....

Key words: *Tuberculosis, Rural and urban, Risk factors*



(Third page onwards: Body of the manuscript)

INTRODUCTION


.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....

METHODOLOGY

.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....

RESULTS


.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....
.....



New page (references)

REFERENCES

1.
.....
.....
.....
2.
.....
.....
.....
3.
.....
.....
.....
4.
.....
.....
.....



New Page (Tables and Figures)

TABLES

Table 1. Age wise distribution of *M. tuberculosis* species

Age	<i>M. tuberculosis</i>	<i>M. avium</i>	<i>M. scrofulacium</i>
15	5	7	7
20	6	6	6
30	7	5	5
50	8	4	3
60	9	3	1

Table 2. Drug Susceptibility Patters of *M. tuberculosis*

Patient No.	Rifampicin	Isoniazide
101	R	R
102	R	R
103	R	R
104	S	S
105	R	R
106	S	S
107	R	R

R, Resistant; S, Susceptible

Comment [r1]: Appropriate footnotes should be provided for abbreviations and symbols used in the table

FIGURE




Figure 1. Preparation of Dried Blood Spot in a DBS paper

Comment [r2]: Format it as it appears
Table 1 (Bold), (full stop) Title of the table (Lower case letter, first letter of sentence should be in capital)